Showing results (1471-1480 of 1,955) with videos related to

Sort By:
Pageof 196
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2009
Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphomaStephen M Ansell, Sara A Hurvitz, Patricia A Koenig, et al.
Blood|July 28, 2019
Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphomaYucai Wang, Brian K Link, Thomas E Witzig, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 27, 2012
Effects of block copolymer properties on nanocarrier protection from in vivo clearanceSuzanne M D'Addio, Walid Saad, Steven M Ansell, et al.
Archives of General Psychiatry|April 6, 2011
Ten-year course of borderline personality disorder: psychopathology and function from the Collaborative Longitudinal Personality Disorders studyJohn G Gunderson, Robert L Stout, Thomas H McGlashan, et al.
Blood|July 15, 2009
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disordersRyan A Wilcox, Andrew L Feldman, David A Wada, et al.
American Journal of Hematology|March 16, 2010
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphomaPatrick B Johnston, David J Inwards, Joseph P Colgan, et al.
Leukemia|April 28, 2023
Characterization of immune exhaustion and suppression in the tumor microenvironment of splenic marginal zone lymphomaTheodora Anagnostou, Zhi-Zhang Yang, Shahrzad Jalali, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|November 13, 2014
Expression of the chemokine receptor gene, CCR8, is associated With DUSP22 rearrangements in anaplastic large cell lymphomaXiaoming Xing, Thomas J Flotte, Mark E Law, et al.
Journal of Patient-Reported Outcomes|March 24, 2026
The PRO-CAR-T™ study: achieving excellence in patient and public involvement and engagementKaren L Shaw, Sarah E Hughes, Olalekan L Aiyegbusi, et al.
Leukemia|May 21, 2010
Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphomaL F Porrata, K Rsitow, D J Inwards, et al.
Pageof 196